预约演示
Isotopia and CPDCCPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
2022-06-09
合作
Centre for Probe Development and Commercialization (CPDC) Logo (CNW Group/Centre for Probe Development and Commercialization)
Isotopia Nuclear Medicine Logo (CNW Group/Centre for ProbeLogoelopment and Commercialization)
Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
TEL AVIV, Israel and HAMILTON, ON, June 9, 2022 /PRNewswire/ - Isotopia Molecular Imaging and the Centre for Probe Development and Commercialization (CPDC) announced that Isotopia's technology for the production of n.c.a. Lu-177 has been successfully transferred into CPDC's GMP facility and that CPDC has shipped its first doses of commercial n.c.a. Lu-177.
n.c.a. Lu-177 is currently the most commonly used radiometal for targeted radiotherapy. As the popularity of the isotope increases, the need for a constant radio-isotope sLu-177on time is essential. Isotopia is thus adding a new production site in North America at CPDC, strengthening its global footprint in the n.c.a. Lu-177 supply chain, ensuring redundancy and shorten delivery time for global supply.
"We havLu-177essfully achieved a stable and reliable n.c.a. Lu-177 supply in North America" said Dr. Bruno Paquin, CEO of CPDC, "CPDC and Isotopia are proud to offer this unique value proposition forIsotopiaclients and beyond, empowering CPDC to become an all-encompassing radiopharmaceutical CDMO."Lu-177
As a global leader specializing in radiopharmaceutical research, development, and manufacturing, Isotopia recognizes the importance of a stable and reliable supply of medical isotopes for manufacturing life-saving therapies.
Isotopia's CEO & Co-Founder, Dr. Eli Shalom, stated "The CPDC manufacturing site is the first steIsotopias Isotopia's global footprint plan to ensure efficient production of Lu-177 and will be added to its existing Drug Master File (DMF). Together with the site in Israel and the near future site in Europe, we create full security of the product to patients on time and great value to pharma companies."
Isotopia moreCPDCut this important milestone, come and meet Lu-177the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 annual meeting, held June 11-14, in Vancouver, BC, Canada where Isotopia Molecular Imaging and CPDC (as AtomVie Global Radiopharma Inc., the new CDMO spin-off of CPDC) will be exhibiting.
The experienced Isotopia team, its nuclear pharmacy, cyclotron facility, Lu-177 production site, and sterile manufacturing plant are well-established platforms for development. Isotopia creates collaborations between the scientific and mAtomVie Global Radiopharma Inc.evelop and experiment with new markers for imaging applications and molecular therapy. For more information about Isotopia, please visit: www.isotopia.co.il
About Isotopiaor Probe Development and Commercialization (CPDC):
The Centre for PIsotopiaelopment and Commercialization (CPDC) is located Lu-177ilton, Ontario, Canada. CPDC is a global leader in the discovery, development and commercializatioIsotopiat-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute foIsotopia Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust and reliable platform for the manufacturing and global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca or contact [email protected]
SOURCE Centre for Probe Development and Commercialization
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。